Sugi Predict

Sugi Predict / Compounds / SCHEMBL593258

SCHEMBL593258

SCHEMBL593258

CC(=O)c1ccc(C(=O)O)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 6/20 0.60
▸ GSK3B P49841 1/20 0.57
▸ LMNA P02545 3/20 0.54
▸ TSHR P16473 1/20 0.54
▸ PKM P14618 1/20 0.54
▸ LIG1 P18858 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.49
▸ MAPT P10636 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ GLA P06280 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ PRNP P04156 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2872059 0.89 GSK3B (0.67) DAOGSK3BLMNATSHRPKM
SCHEMBL3012845 0.89 KDM4E (0.61) DAOLMNATSHRPKMLIG1
SCHEMBL70493 0.87 DAO (0.67) DAOPKMLIG1RAB9AALDH1A1
SCHEMBL28353716 0.84 DAO (0.64) DAOPKMLIG1RAB9AALDH1A1
SCHEMBL11598753 0.84 DAO (0.64) DAOPKMLIG1RAB9AALDH1A1
SCHEMBL29808747 0.84 DAO (0.64) DAOPKMLIG1RAB9AALDH1A1
Hydrochloric Acid SCHEMBL1979156 0.84 DAO (0.64) DAOPKMLIG1RAB9AALDH1A1
SCHEMBL19987844 0.84 DAO (0.64) DAOPKMLIG1RAB9AALDH1A1
Hydrochloric Acid SCHEMBL3074364 0.84 DAO (0.64) DAOPKMLIG1RAB9AALDH1A1
Alcohol SCHEMBL28943550 0.80 DAO (0.60) DAOGSK3BPKMLIG1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114773312-B Preparation process of alolol hydrochloride intermediate 北京鑫诺康桥药物研究有限公司 2024-03-26 — — CN claimed
CN-117003728-A 5-acetylthiophene-2-carboxylic acid intermediate and preparation method thereof 深圳市茵诺圣生物科技有限公司 2023-11-07 — — CN claimed
CN-114773312-A Preparation process of arotinolol hydrochloride intermediate 成都硕德药业有限公司 2022-07-22 — — CN claimed
CN-104447731-B Preparation method of 2-formylamine-5-(2-sulfhydryl-1, 3-thiazole-4-base)-thiophene 千辉药业（安徽）有限责任公司 2017-01-18 — — CN claimed
CN-103613586-B A kind of pure S-of optically-active (-)-arotinolol acid salt and its preparation method and application 北京博爱旺康医药科技有限公司 2016-06-08 — — CN claimed
CN-104447731-A Preparation method of 2-formylamine-5-(2-sulfhydryl-1, 3-thiazole-4-base)-thiophene CHEER FINE PHARMACEUTICAL ANHUI CO LTD 2015-03-25 — — CN claimed
CN-103613586-A Optically sensitive pure S-(-)-arotinolol acid salt, preparation method and applications thereof BEIJING BOAI WANGKANG MEDICAL TECHNOLOGY CO LTD 2014-03-05 — — CN claimed
US-7842810-B2 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide JANSSEN PHARMACEUTICA, NV (BE) 2010-11-30 — — US claimed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 — — US claimed
EP-2149551-A1 N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 — — EP claimed
US-20060223810-A1 Bicyclic pyrazole compounds as antibacterial agents JANSSEN PHARMACEUTICA N.V. (BE) 2006-10-05 — — US claimed
WO-2006105289-A1 BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2006-10-05 — — WO claimed
CN-1259307-C Acylated indanyl amines and their use as pharmaceuticals AVENTIS PHARMA GMBH (DE) 2006-06-14 — — CN claimed
EP-1631560-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-03-08 — — EP claimed
US-20050004112-A1 C-fms kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2005-01-06 — — US claimed
WO-2004096795-A2 C-FMS KINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2004-11-11 — — WO claimed
CN-1491207-A Acylated indanyl amines and their use as pharmaceuticals ������ҽҩ�¹����޹�˾ 2004-04-21 — — CN claimed
US-5101049-A Novel thiophene derivatives and methods for producing the same SEITETSU KAGAKU CO., LTD. (JP) 1992-03-31 — — US claimed
US-4153610-A Process for producing 5-carboxy-2-acetylthiophene SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-05-08 — — US claimed
US-4130566-A Process for producing 5-carboxy-2-acetylthiophene SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1978-12-19 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223810-A1 Bicyclic pyrazole compounds as antibacterial agents NOD2, BAK1, CASP3 DAO 1002/4885GSK3B 3149/4885LMNA 2909/4885
US-20050004112-A1 C-fms kinase inhibitors FLT3, FGR, FER DAO 1965/4885GSK3B 184/4885LMNA 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.